HENGRUI Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

The HSI concluded the midday up 102 points or 0.4% at 25,490. The HSCEI rose 7 points or less than 0.1% to 9,157. The HSTECH fell 33 points or 0.6% to 5,644. The total market turnover at midday reached HKD149.725 billion.TENCENT (00700.HK), JD-SW (09618.HK), and BABA-W (09988.HK) have released their AI products and specification......

GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights......

OTTAWA (dpa-AFX) - Hengrui Pharma announced that it has entered into a series of strategic agreements with GSK plc (GSK, GSK.L) to jointly develop up to 12 innovative medicines. These programs are......

Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company's potential chronic lung disease treatment....

HENGRUI PHARMA (01276.HK) announced the signing of strategic cooperation agreements with GSK, granting GSK an exclusive worldwide right excluding Mainland China, Hong Kong, Macau and Taiwan, to its innovative drug PDE3/4 inhibitor HRS-9821 for the treatment of chronic obstructive pulmonary disease (COPD), as well as options for ......

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completion JIANGSU, China, July 27, 2025 /PRNewswire/ -- Hengrui Pharma......

HENGRUI PHARMA (01276.HK) opened with an upside gap of 10.65% today (28th). It last printed at $75.3, on pre-market volume of 296,400 shares and turnover of $22.3189 million.HENGRUI PHARMA announced that it had entered into agreements with GSK to grant GSK an exclusive worldwide right of HRS-9821, as well as exclusive options to......

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial Data will include patients from the dose escalation and at multiple expansion doses U.S. Phase 1 trial of IDE849 in SCLC......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe....

Jiangsu Hengrui Pharmaceuticals Co. and its US partner said their obesity drug candidate succeeded in a late-stage China study, a key step toward securing approval as domestic biotech firms increasingly challenge foreign rivals....

HENGRUI PHARMA (01276.HK) opened 1.7% higher this morning and once hit an intraday high of HKD66.25. It was last at HKD64.6, up 7.3%.Citi, the sponsor of HENGRUI PHARMA, released a report giving the company's H-shares a Buy rating for the first time with a target price of HKD134. The broker considers the company a leader and......

Morgan Stanley released a research report, covering HENGRUI PHARMA (01276.HK), which possesses the most extensive and balanced product portfolio and pipeline among domestic pharmaceutical companies in China. The company estimated to have 47 new drugs approved for market launch between 2025 and 2027. Since 2018, the company has e......